Comparative Pharmacology
Head-to-head clinical analysis: FERABRIGHT versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERABRIGHT versus SESQUIENT.
FERABRIGHT vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy: provides elemental iron for erythropoiesis, correcting iron deficiency anemia.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
Intravenous bolus of 100 mg ferric carboxymaltose (elemental iron), administered no more than 3 times per week until iron repletion is achieved.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Renal elimination of unchanged drug accounts for approximately 60-70% of total clearance, with biliary/fecal excretion contributing 20-30%. The remainder undergoes hepatic metabolism.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement